Eisai Alzheimer’s drug Leqembi shows early signs of momentum shift - Bernstein

Eisai's Alzheimer’s drug, Leqembi, is showing promising early signs of a momentum shift, according to Bernstein analysts. This development is significant as it suggests that the drug may be gaining traction in the market, potentially offering new hope for patients and families affected by Alzheimer’s disease. The positive outlook could lead to increased investment in Alzheimer's research and treatment options, making a real difference in the lives of those battling this challenging condition.